medroxyprogesterone

Generic Name: medroxyprogesterone

Clinical Trials

Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women

Not Applicable

Completed

Conditions: Cognitive Impairment
Cardiovascular Disease
Executive Dysfunction
Endothelial Dysfunction

Interventions: Drug: Leuprolide acetate
Drug: Placebo
Drug: Estradiol
Drug: Medroxyprogesterone

First Posted Date: 2014-04-24

Last Posted Date: 2022-01-10

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 17

Registration Number: NCT02122198

Locations: 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸
University of Colorado Boulder Intermountain Neuroimaging Consortium, Boulder, Colorado, United States

Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Phase 3

Completed

Conditions: Kidney Cancer

First Posted Date: 2006-12-28

Last Posted Date: 2012-09-26

Lead Sponsor: Centre Leon Berard

Target Recruit Count: 456

Registration Number: NCT00416429

Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer

Phase 3

Completed

Conditions: Hot Flashes
Breast Cancer
Menopausal Symptoms

First Posted Date: 2003-09-17

Last Posted Date: 2023-06-15

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00026286

Locations: 🇺🇸
CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸
CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States
🇺🇸
CCOP - Northern New Jersey, Hackensack, New Jersey, United States

and more 21 locations

Alzheimer's Disease: Therapeutic Potential of Estrogen

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Transdermal estradiol
Drug: Medroxyprogesterone
Drug: Placebo
Drug: Placebo Patch

First Posted Date: 2003-08-05

Last Posted Date: 2018-08-23

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 42

Registration Number: NCT00066157

Locations: 🇺🇸
University of Wisconsin Memory Research Program, Madison, Wisconsin, United States

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

Phase 2

Completed

Conditions: Endometrial Adenocarcinoma
Endometrial Adenosquamous Carcinoma
Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
Recurrent Uterine Corpus Carcinoma
Stage I Uterine Corpus Cancer
Stage II Uterine Corpus Cancer
Stage III Uterine Corpus Cancer
Stage IV Uterine Corpus Cancer

Interventions: Other: Laboratory Biomarker Analysis
Drug: Medroxyprogesterone
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2003-07-09

Last Posted Date: 2016-04-11

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 75

Registration Number: NCT00064025

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer

Phase 2

Terminated

Conditions: Endometrial Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-10

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 360

Registration Number: NCT00003179

Locations: 🇺🇸
State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States
🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States

and more 28 locations

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

Phase 2

Completed

Conditions: Endometrial Cancer

Interventions: Drug: medroxyprogesterone
Drug: ethinyl estradiol
Other: laboratory biomarker analysis
Drug: norgestrel

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 52

Registration Number: NCT00033358

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

S9630, Medroxyprogesterone in Treating Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer
Endometrial Cancer

Interventions: Drug: tamoxifen citrate
Drug: medroxyprogesterone
Procedure: adjuvant therapy

First Posted Date: 2003-01-27

Last Posted Date: 2012-10-31

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 313

Registration Number: NCT00002920

Locations: 🇺🇸
CCOP - Beaumont, Royal Oak, Michigan, United States
🇺🇸
Veterans Affairs Medical Center - Loma Linda (Pettis), Loma Linda, California, United States
🇺🇸
Veterans Affairs Medical Center - Asheville, Asheville, North Carolina, United States

and more 119 locations

Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women

Phase 3

Completed

Conditions: Hot Flashes

Interventions: Drug: medroxyprogesterone
Drug: venlafaxine

First Posted Date: 2003-01-27

Last Posted Date: 2016-07-13

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 227

Registration Number: NCT00030914

Locations: 🇺🇸
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
🇺🇸
Coborn Cancer Center, Saint Cloud, Minnesota, United States
🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States

and more 19 locations

Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus

Not Applicable

Completed

Conditions: Systemic Lupus Erythematosus

First Posted Date: 2000-08-04

Last Posted Date: 2005-06-24

Lead Sponsor: National Center for Research Resources (NCRR)

Target Recruit Count: 970

Registration Number: NCT00006133

Locations: 🇺🇸
Louisiana State University School of Medicine, Shreveport, Louisiana, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Pritzker School of Medicine, Chicago, Illinois, United States

and more 14 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy